Burzynski Research Institute (BZYR) Accounts Payables (2011 - 2025)
Burzynski Research Institute (BZYR) posted Accounts Payables of $45101.0 for Q4 2025, up 88.37% sequentially from $23943.0 in Q3 2025, and up 153.65% YoY from $17781.0 in Q4 2024.
Burzynski Research Institute (BZYR) Accounts Payables (2011 - 2025) Analysis & Trends
Burzynski Research Institute has reported Accounts Payables for 15 years, with the latest figure at $45101.0 in Q4 2025.
- Quarterly Accounts Payables rose 153.65% year-over-year to $45101.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was $45101.0 (up 153.65% YoY) and the FY2025 annual result came in at $17017.0, up 88.87% from the prior year.
- Accounts Payables advanced to $45101.0 in Q4 2025 per BZYR's latest filing, from $23943.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $77303.0 in Q3 2024 and troughed at $1389.0 in Q4 2021.
- A 5-year average of $25437.8 and a median of $19630.0 in 2021 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2021 and 2022: Accounts Payables tumbled 93.57% in 2021, then soared 1098.7% in 2022.
- Over 5 years, Accounts Payables stood at $1389.0 in 2021, then jumped by 1098.7% to $16650.0 in 2022, then increased by 20.12% to $20000.0 in 2023, then dropped by 11.1% to $17781.0 in 2024, then soared by 153.65% to $45101.0 in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $45101.0, $23943.0, and $25682.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | 45,101.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 45,101.00 |
| Aug 31, 2025 | 23,943.00 |
| May 31, 2025 | 25,682.00 |
| Feb 28, 2025 | 17,017.00 |
| Nov 30, 2024 | 17,781.00 |
| Aug 31, 2024 | 77,303.00 |
| May 31, 2024 | 70,605.00 |
| Feb 29, 2024 | 9,010.00 |
| Nov 30, 2023 | 20,000.00 |
| May 31, 2023 | 22,757.00 |
| Feb 28, 2023 | 12,570.00 |
| Nov 30, 2022 | 16,650.00 |
| Aug 31, 2022 | 1,935.00 |
| May 31, 2022 | 13,925.00 |
| Nov 30, 2021 | 1,389.00 |
| Aug 31, 2021 | 19,260.00 |
| May 31, 2021 | 30,441.00 |
| Feb 28, 2021 | 32,512.00 |
| Nov 30, 2020 | 21,604.00 |
| Aug 31, 2020 | 86,140.00 |